Valuation: IXICO plc

Market Cap 16.35M 22.16M 19.14M 17.98M 30.75M 2.12B 31.25M 211M 82.38M 1.06B 83.18M 81.38M 3.53B P/E 2026 *
-5.36x
P/E 2027 * -5.77x
Enterprise Value 6.15M 8.34M 7.2M 6.77M 11.57M 797M 11.76M 79.28M 31M 399M 31.3M 30.62M 1.33B EV / Sales 2026 *
0.77x
EV / Sales 2027 * 1.14x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
1 week+1,000.00%
Current month+1,000.00%
1 month+1,000.00%
3 months+1,000.00%
6 months+1,000.00%
Current year+1,000.00%
3 years 0.07
Extreme 0.07
0.77
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+1,000.00% - - 22.16M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -0.60%+0.49%+78.02%+110.46% 29.24B
Weighted average by Cap. -0.91%+0.59%+95.83%+132.95%

Financials

2026 *2027 *
Net sales 8M 10.84M 9.36M 8.8M 15.04M 1.04B 15.29M 103M 40.3M 519M 40.69M 39.81M 1.72B 9M 12.19M 10.53M 9.9M 16.92M 1.17B 17.2M 116M 45.34M 584M 45.78M 44.79M 1.94B
Net income -2.14M -2.9M -2.51M -2.36M -4.03M -278M -4.1M -27.61M -10.8M -139M -10.9M -10.66M -462M -2.8M -3.79M -3.28M -3.08M -5.27M -363M -5.35M -36.09M -14.11M -182M -14.25M -13.94M -604M
Net Debt -10.2M -13.82M -11.94M -11.22M -19.18M -1.32B -19.49M -131M -51.38M -662M -51.88M -50.76M -2.2B -6.1M -8.26M -7.14M -6.71M -11.47M -790M -11.66M -78.59M -30.73M -396M -31.03M -30.35M -1.32B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0750GBP
Average target price
0.2600GBP
Spread / Average Target
+246.67%

Annual profits - Rate of surprise